Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
09 mai 2024 07h00 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
07 mai 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22 avr. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
16 avr. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
13 mars 2024 16h22 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11 mars 2024 07h42 HE
|
Lexeo Therapeutics
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11 mars 2024 07h30 HE
|
Lexeo Therapeutics
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
05 févr. 2024 07h00 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
LEXEO Therapeutics
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
18 déc. 2023 07h00 HE
|
LEXEO Therapeutics
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic